LUMOSA THERAPEUTICS CO LTD 6535
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 549.97
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
LUMOSA THERAPEUTICS CO LTD develops new drugs. The company is engaged in the development of drugs for unmet medical needs in the fields of CNS, oncology, and inflammatory diseases. Geographically, it derives a majority of its revenue from Asia and also has a presence in Taiwan, Europe, and America. Its product pipeline is Neuroscience which includes LT 1001 for Postoperative Pain, LT 3001 for Acute Ischemic Stroke, LT 5001 for Uremic Pruritus, LT 6001 for Neurological disorder, and Oncology including LT 2003 for Solid Tumor. It generates revenue from sales of goods.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 38
- Website
- https://www.lumosa.com.tw
Comparables
Valuation
|
Metric
|
6535
|
6696
|
6919
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 23.15 | 3.52 | 15.09 |
Price/Sales | 549.97 | — | 601.41 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
6535
|
6696
|
6919
|
|---|---|---|---|
Quick Ratio | 3.98 | 13.67 | 31.07 |
Current Ratio | 4.75 | 14.10 | 31.28 |
Interest Coverage | −5,543.09 | −647.17 | −1,381.29 |
Quick Ratio
6535
6696
6919
Profitability
|
Metric
|
6535
|
6696
|
6919
|
|---|---|---|---|
Return on Assets (Normalized) | −22.08% | −37.22% | −20.90% |
Return on Equity (Normalized) | −25.48% | −61.30% | −21.62% |
Return on Invested Capital (Normalized) | −25.35% | −39.00% | −22.12% |
Return on Assets
6535
6696
6919
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ntxtcnjm | Wfzc | $586.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Cdzhdrd | Lhkjzw | $115.1 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ksrzjgbd | Mxmbww | $108.2 Bil | |
MRNA
| Moderna Inc | Jzctpzr | Wmff | $54.0 Bil | |
ARGX
| argenx SE ADR | Rfhpmbqvz | Lhp | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Vbvbxkwp | Ngz | $21.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mjxdxgrq | Wlynqyx | $18.9 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fwrffxkf | Tpctvf | $14.6 Bil | |
INCY
| Incyte Corp | Kwsjghtpd | Hsmsbm | $12.9 Bil | |
RPRX
| Royalty Pharma PLC Class A | Lbbmybcvtt | Wfcxbm | $12.3 Bil |